Catalent Inc (NASDAQ:CTLT)‘s stock had its “hold” rating restated by equities researchers at Needham & Company LLC in a research note issued to investors on Monday.

Other analysts have also recently issued research reports about the stock. BidaskClub cut shares of Catalent from a “buy” rating to a “hold” rating in a research note on Friday, September 15th. Piper Jaffray Companies reiterated a “buy” rating and issued a $45.00 price objective on shares of Catalent in a research note on Tuesday, August 29th. Bank of America Corporation reiterated a “buy” rating and issued a $40.00 price objective (up previously from $38.00) on shares of Catalent in a research note on Tuesday, August 29th. Zacks Investment Research cut shares of Catalent from a “buy” rating to a “hold” rating in a research note on Friday, August 18th. Finally, ValuEngine upgraded shares of Catalent from a “hold” rating to a “buy” rating in a research note on Thursday, September 7th. Five investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $40.56.

Catalent (NASDAQ:CTLT) traded up 0.47% during mid-day trading on Monday, reaching $42.94. 462,219 shares of the company were exchanged. The company’s 50 day moving average price is $41.11 and its 200-day moving average price is $35.99. The stock has a market capitalization of $5.38 billion and a price-to-earnings ratio of 49.36. Catalent has a 12-month low of $21.83 and a 12-month high of $43.39.

Catalent (NASDAQ:CTLT) last issued its quarterly earnings data on Monday, August 28th. The company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.08. Catalent had a net margin of 10.02% and a return on equity of 36.29%. The business had revenue of $616.90 million during the quarter, compared to analysts’ expectations of $547.48 million. During the same quarter in the previous year, the company earned $0.52 EPS. The business’s revenue was up 15.9% on a year-over-year basis. On average, equities research analysts forecast that Catalent will post $1.63 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/24/catalent-inc-ctlt-stock-rating-reaffirmed-by-needham-company-llc.html.

In other Catalent news, SVP Christine Dolan sold 1,594 shares of the firm’s stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $38.75, for a total value of $61,767.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of hedge funds have recently added to or reduced their stakes in the business. Acrospire Investment Management LLC grew its holdings in shares of Catalent by 72.2% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock valued at $109,000 after purchasing an additional 1,300 shares during the last quarter. Quantbot Technologies LP grew its holdings in shares of Catalent by 110.7% during the 2nd quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock valued at $120,000 after purchasing an additional 1,804 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Catalent by 66.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 6,070 shares of the company’s stock valued at $173,000 after purchasing an additional 2,425 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Catalent by 12.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock valued at $177,000 after purchasing an additional 559 shares during the last quarter. Finally, Advisor Group Inc. grew its holdings in shares of Catalent by 1.3% during the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock valued at $180,000 after purchasing an additional 65 shares during the last quarter.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Analyst Recommendations for Catalent (NASDAQ:CTLT)

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.